Evidence map›Paper›PMID 35610098›Full record

ArticleRevue neurologique2022

Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study.

C Vialatte de Pémille, A Ray, A Michel, F Stefano, T Yim, C Bruel, M Zuber

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Revue neurologique, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04468035 (Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04468035 completednot on this map

Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS (Acute Respiratory Distress Syndrome) on SARS-CoV2 Viral Pneumonia Requiring Mechanical Ventilation

TypeobservationalSponsorFondation Hôpital Saint-JosephRan2020 to 2022Enrolled22ConditionsCovid19
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

C Vialatte de PémilleNeurological department, groupe hospitalier Paris Saint-Joseph, Paris, France; Université Paris Cité, Paris, France. Electronic address: cvialatte@ghpsj.fr.
A RayNeurological department, groupe hospitalier Paris Saint-Joseph, Paris, France; Université Paris Cité, Paris, France.
A MichelNeurological department, groupe hospitalier Paris Saint-Joseph, Paris, France.
F StefanoNeurological department, groupe hospitalier Paris Saint-Joseph, Paris, France.
T YimNeurological department, groupe hospitalier Paris Saint-Joseph, Paris, France.
C BruelIntensive care unit, groupe hospitalier Paris Saint-Joseph, Paris, France.
M ZuberNeurological department, groupe hospitalier Paris Saint-Joseph, Paris, France; Université Paris Cité, Paris, France.
Hôpital Paris Saint-Joseph · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCOVID-19 due to SARS-CoV-2 virus is a new cause of severe acute respiratory syndrome (SARS). Little is known about the short-term cognitive prognosis for these patients. We prospectively evaluated basic cognitive functions shortly after care in the intensive care unit (ICU) and three months later in post-ICU COVID-19 patients. MATERIAL AND

methodsWe performed a prospective single-center study in our institution in Paris. Patients with SARS-CoV-2 SARS were prospectively recruited via our ICU. Patients were evaluated using standardized cognitive tests at baseline and at three months' follow-up. Our primary endpoint was the evolution of the following five global tests: MMSE, FAB, oral naming test, Dubois five words test and MADRS.

resultsWe explored 13 patients at baseline and follow-up. All patients had cognitive impairment at baseline but they all improved at three months, significantly on two of the five global tests after Bonferroni correction for multiple testing: MMSE (median 18 (IQR [15-22]) and 27 (IQR [27-29]) respectively, P=0.002) and FAB test (median 14 (IQR [14-17]) and 17 (IQR [17,18]) respectively, P=0.002).

conclusionsWe report here the first longitudinal data on short-term cognitive impairment after intensive care in COVID-19 patients. We found acute and short-term cognitive impairment but significant improvement at three months. This pattern does not seem to differ from other causes of post-intensive care syndrome.

Indexed as

Cognitive DysfunctionCOVID-19Critical IllnessHumansIntensive Care UnitsPrevalenceSARS-CoV-2Cognitive disorderCOVID-19Critical care syndromeExecutive functionSARS-CoV-2

Identifiers

PMID35610098
PMCPMC9123423
OpenAlexW4280562032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.